CuraCell Biotech

CuraCell Biotech is a biotechnology company headquartered in Suzhou, China, focused on developing next-generation chimeric antigen receptor T-cell (CAR-T) therapies for solid tumors. The company leverages its proprietary armored CAR-T platform to enhance the efficacy and persistence of T-cells within the challenging immunosuppressive microenvironment of solid malignancies. Its pipeline includes programs targeting high-value antigens such as Claudin 18.2, Mesothelin, and GPC3, with a primary focus on gastric, pancreatic, and liver cancers. Founded in 2021 and backed by prominent venture capital firms, CuraCell Biotech aims to address significant unmet medical needs in oncology through innovative cell engineering and advanced manufacturing capabilities.